Acute decompensated heart failure (ADHF) in children is rising in incidence, carries higher per-patient mortality than adult heart failure, and remained without standardized management guidance — until now. The 2026 American Heart Association (AHA) Scientific Statement Evaluation and Management of the Child With Acute Decompensated Heart Failure (Cabrera et al.) provides the first comprehensive guidance document for evaluating, managing, and discharging children presenting with ADHF, spanning the emergency department through the intensive care unit and inpatient floor. This article distills the key clinical takeaways for pediatric hospitalists, intensivists, cardiologists, and emergency providers.

Why Pediatric ADHF Is Different

Pediatric heart failure is not adult heart failure in a smaller body. The causes are fundamentally different: congenital heart disease (CHD) accounts for the majority of pediatric HF-related emergency department visits (46.6%) and hospitalizations (62.7%), followed by arrhythmias and conduction disorders and then cardiomyopathy. Dilated cardiomyopathy is the most common cardiomyopathy subtype (approximately 50%), and about 40% of children presenting with symptomatic dilated cardiomyopathy undergo heart transplantation or die within the first 2 years of diagnosis.

The burden is increasing. Between 2012 and 2016, comorbid HF emergency department visits nearly doubled (rate ratio 1.93), and primary HF hospitalizations increased significantly (rate ratio 1.14). Compared with adults, children with HF have higher in-hospital mortality and use significantly more advanced therapies including extracorporeal membrane oxygenation (ECMO), ventricular assist devices (VAD), and cardiac transplantation.

Recognizing ADHF: It Can Mimic Sepsis

A critical point from the AHA 2026 statement: ADHF can mimic sepsis in the pediatric emergency department. A hypotensive child with tachycardia, poor perfusion, and altered mental status may be in cardiogenic shock rather than septic shock. Administering aggressive intravenous fluid boluses to a child in ADHF can be catastrophic, precipitating pulmonary edema and respiratory failure. Frontline clinicians should carefully evaluate before initiating sepsis protocols or administering IV fluids.

Initial assessment should determine whether the patient presents with features of low cardiac output (altered mental status, reduced urine output, poor pulses, cool extremities) or congestion (jugular venous distention, pulmonary crackles, hepatomegaly, gallop rhythm, peripheral edema), or both — because each profile has distinct management implications.

Hemodynamic Profiling: Warm/Cold, Wet/Dry

The AHA statement adapts the Stevenson hemodynamic profiling framework for pediatric use:

Profile	Congestion	Low Perfusion	Clinical Features
Warm and Dry	No	No	Compensated; monitor closely
Warm and Wet	Yes	No	Tachypnea, hepatomegaly, edema; diuretics are primary therapy
Cold and Dry	No	Yes	Narrow pulse pressure, cool extremities, AKI; cautious fluids, consider inotropes
Cold and Wet	Yes	Yes	Most severe; requires diuretics AND inotropes or vasopressors

In children, signs of congestion include tachypnea, respiratory distress (grunting), and hepatomegaly. In older patients, jugular venous distention and peripheral edema become more apparent. Signs of low perfusion include narrow pulse pressure, agitation, poor oral intake, cool extremities, and acute kidney injury.

Cardiogenic Shock: The SCAI Staging System

Approximately 1 in 4 children with ADHF presents in cardiogenic shock, with mortality increasing in a graded fashion with each SCAI stage. The modified pediatric SCAI classification is as follows:

Stage A ("At Risk"): Hemodynamically stable, normal perfusion, but at risk for cardiogenic shock. Mortality approximately 7%.
Stage B ("Beginning"): Hypotension OR vasoactive medications, but normal perfusion.
Stage C ("Classic"): Hypotension AND vasoactive medications, OR features of hypoperfusion (cool extremities, lactate >2 mmol/L).
Stage D ("Deteriorating"): Requires more than two vasoactive medications or mechanical circulatory support.
Stage E ("Extremis"): Circulatory collapse requiring cardiopulmonary resuscitation. Mortality approximately 36%.

The undulant nature of pediatric cardiogenic shock stages can provide false reassurance. Late worsening in shock severity is associated with increased mortality, paralleling findings in adults. Serial reassessment is essential throughout the hospital course.

Emergency Department Management

The AHA statement outlines a systematic approach to ED management.

Initial workup: complete blood count, comprehensive metabolic panel, lactate, and NT-proBNP or BNP; 12-lead ECG to identify arrhythmias; chest radiograph to evaluate for cardiomegaly and pulmonary congestion; and early echocardiography or point-of-care cardiac ultrasound.

NT-proBNP and BNP provide important diagnostic and prognostic information. In children with CHD, natriuretic peptide levels correlate with ventricular volumes, ventricular function, and worsening functional class, though normative values are age-dependent and are typically higher in infants.

Diuretics: Intravenous loop diuretics are the cornerstone of decongestive therapy. For patients on chronic diuretics, the DOSE trial supports starting IV dosing at 1 to 2.5 times the total oral daily dose, divided and administered every 12 hours.

Respiratory support: Noninvasive ventilation (CPAP or BiPAP) can improve oxygenation, reduce respiratory muscle effort, and hemodynamically reduce right ventricular preload and left ventricular afterload. Caution is warranted in isolated right heart failure, where positive pressure may increase RV afterload and precipitate decompensation.

Critical warning on intubation: Elective or emergent intubation carries a high risk of cardiac arrest in ADHF due to sedation-induced hypotension, vagal tone changes, and decreased cardiac output. ECMO team activation for standby preparedness has become routine practice at comprehensive pediatric heart centers.

Vasoactive initiation — timing matters: In adults, administration of vasodilators or inotropes within 6 hours of admission is associated with better survival and shorter hospital stays. In children, starting vasoactive agents in the ED rather than waiting for ICU transfer results in significantly shorter time to initiation.

ICU admission criteria: Respiratory distress, unstable arrhythmias, complex CHD, need for vasoactives or inotropes, or need for narcotics for comfort.

Inotrope Selection

The 2025 AHA/AAP PALS guidelines provide a Class 2b recommendation that epinephrine, dopamine, dobutamine, or milrinone may be reasonable as inotropic infusions for pediatric cardiogenic shock. The AHA ADHF statement provides more detailed guidance on agent selection.

Milrinone (phosphodiesterase III inhibitor):

Starting dose 0.25 µg/kg/min, titrate up to 0.75 µg/kg/min.
Increases inotropy, improves lusitropy, decreases systemic vascular resistance and pulmonary vascular resistance.
Long half-life (1–4 hours); reduce dose in acute kidney injury.
Retains efficacy with concurrent β-blockers because its mechanism is independent of β-adrenergic receptors.
Most commonly used for chronic bridging to transplantation or MCS.
A systematic review found milrinone significantly improved LVEF (weighted mean difference 3.41), cardiac index (WMD 0.50), and serum lactate (WMD −0.59), though questions remain about its true inotropic versus vasodilatory mechanism.
Long-term IV milrinone (median 27 days) in pediatric dilated cardiomyopathy is safe, with cardiac function recovery in approximately 60% of patients.

Epinephrine:

Standard of care for resuscitation and rescue of the circulation in pediatric ADHF.
At doses 0.05–0.1 µg/kg/min: β-1 (inotropy) and β-2 (vasodilation) effects.
At doses >0.1 µg/kg/min: α-adrenergic vasoconstriction predominates.
More potent inotrope than dopamine, with stronger α-1 receptor activity.
Risks include tachyarrhythmias and increased myocardial oxygen demand.

Dobutamine (2–20 µg/kg/min):

Primarily β-1 stimulation (inotropy and chronotropy).
At doses around 5 µg/kg/min, peripheral β-2 vasodilation occurs; higher doses cause vasoconstriction.
Short half-life (2–3 minutes), rapid onset.
Generally not preferred due to increased dysrhythmia risk and tachyphylaxis.

Dopamine:

3 µg/kg/min: D1 receptor activation (historically described as enhancing renal perfusion, though the ROSE AHF trial showed no benefit of low-dose dopamine for decongestion or renal function).
3–10 µg/kg/min: β-1 stimulation (inotropy and chronotropy).
>10 µg/kg/min: α-receptor activation (vasoconstriction).

Hemodynamic Monitoring

The European Society of Paediatric and Neonatal Intensive Care consensus, endorsed by the AHA ADHF statement, recommends the following. Strong agreement exists for standard invasive measurements including blood pressure, central venous pressure, mixed venous oxygen saturation, serial lactate, clinical perfusion assessment, and near-infrared spectroscopy (NIRS). There is weak agreement for thermodilution catheters in refractory cardiogenic shock. Pulmonary arterial catheters to measure cardiac output in children are recommended against. Pulmonary artery pressure monitoring has shown no benefit in reducing HF hospitalizations in pediatric patients, including in small series of adult Fontan patients.

Mechanical Circulatory Support

When ADHF is refractory to medical management, mechanical circulatory support (MCS) is the next step. The 2025 AHA/AAP PALS guidelines emphasize that early ECMO cannulation of patients requiring invasive ventilation may be associated with improved survival, particularly in myocarditis, where transplant-free survival to discharge ranges from 72% to 80%.

ECMO is the most widely used MCS modality for pediatric ADHF globally. It provides biventricular and respiratory support. Peripheral cannulation (femoral in older children, cervical in infants) allows rapid deployment. A key limitation is that peripheral ECMO increases LV afterload, potentially hindering ventricular recovery.

LV distention on VA-ECMO is a frequent complication due to afterload mismatch. Pediatric patients may have worse LV compliance than adults, placing them at greater risk. Evidence of LV distention includes loss of arterial pulsatility, pulmonary edema, lack of aortic valve opening on echocardiography, or signs of intracardiac stasis. Decompression strategies include balloon atrial septostomy, percutaneous or surgical LV vent placement, or addition of a percutaneous microaxial pump such as Impella.

VADs: Durable VAD support has experienced exponential growth in pediatric use. According to the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs), indications include bridge to transplantation (48%), bridge to candidacy (38%), and bridge to recovery (9%).

Myocardial recovery occurs in approximately 5% of adult patients on VAD support, though pediatric data suggest more favorable results in select populations. One of the largest pediatric studies reported 84% event-free survival and 83% sustained functional capacity Class 1 at 10 years after VAD explantation.

Nutrition: An Underrecognized Priority

The prevalence of wasting in pediatric HF has been reported to be as high as 86%. The AHA statement emphasizes prioritizing enteral nutrition within the first 48 hours of admission once the patient is hemodynamically stable. Gastric feeding is preferred for gut integrity maintenance and lower metabolic complication risk. Parenteral nutrition should be withheld for 7 days if the enteral route is feasible; a multicenter randomized controlled trial of 1,440 critically ill children (more than 35% of whom were cardiac patients) showed that withholding early parenteral nutrition was clinically superior, with shorter mechanical ventilation, less renal replacement therapy, and shorter hospital stays. Nutritional calculations should use euvolemic weight (the lowest weight within a 7-day period) to avoid overfeeding in the setting of fluid overload.

Transitioning to Oral Therapies: A Major Gap

A striking finding from the AHA statement: only about 65% of children with ADHF are prescribed an ACE inhibitor or ARB at discharge, and approximately 20% receive the standard triple combination of ACEi or ARB, β-blocker, and aldosterone antagonist. Prescription rates have not changed significantly over the past decade, representing a major quality improvement opportunity.

In adults, guideline-directed medical therapy (GDMT) with quadruple therapy (ARNi or ACEi or ARB, β-blocker, MRA, SGLT2 inhibitor) is the standard of care. In children, no large randomized controlled trials have identified consistently effective therapies for symptomatic HF, though most pediatric cardiomyopathy patients are treated with ACE inhibitors (98%), MRAs (79%), and β-blockers (76%) based on extrapolation from adult data.

Sacubitril/valsartan (Entresto) is now FDA-approved for treatment of symptomatic HF with systemic LV systolic dysfunction in pediatric patients aged 1 year and older. Safety and efficacy data for SGLT2 inhibitors are currently lacking in children with HF.

Readmission: The Unresolved Problem

Readmission rates for pediatric HF are alarmingly high and have not declined over the past decade. At 30 days, approximately 20% of children with HF are readmitted versus 3.1% of children without HF. At 60 days, readmission rates reach approximately 30% versus 4.3% in children without HF. Infants are at highest risk for readmission, and teenage readmission rates are rising. Children with HF who are readmitted have 7-fold higher mortality and 4.5-fold higher hospital charges than children without HF.

Risk factors for readmission include single ventricle anatomy (odds ratio 1.7), chromosomal anomaly (OR 1.8), cardiomyopathy (OR 3.3), tube feeding (OR 1.6), and increased index length of stay (OR 1.5).

Behavioral Health: Do Not Forget the Family

Children with HF are at heightened risk of anxiety, depression, and acute or posttraumatic stress, especially those with prolonged hospital stays. This burden extends to caregivers and family members. The AHA statement recommends regular mental health screening for patients and caregivers, integration of mental health professionals into the cardiac care team, and access to psychotherapy and peer support groups.

The Systematic Approach: ED → ICU → Floor → Discharge

The AHA statement proposes a structured three-phase framework ensuring continuity across the hospital course.

Emergency Department: Identify hemodynamic profile (low output versus congestion). Obtain BNP or NT-proBNP, chest radiograph, ECG, and echocardiogram. Start IV loop diuretics. Initiate noninvasive respiratory support and vasoactives as needed. Determine ICU admission criteria.

Intensive Care Unit: Establish hemodynamic monitoring (central venous pressure, NIRS, mixed venous oxygen saturation, arterial blood pressure). Determine cardiogenic shock stage. Assess MCS needs. Use intermittent or continuous loop diuretics. Escalate to endotracheal intubation with ECMO standby when needed. Start nutrition and rehabilitation. Wean vasoactives and begin oral HF therapies.

Inpatient Floor: Advance oral HF therapies to therapeutic doses. Continue nutrition and rehabilitation. Obtain surveillance BNP, echocardiogram, and clinical monitoring. Complete discharge planning with an early return appointment within 7–14 days.

Key Clinical Priorities

ADHF can mimic sepsis — evaluate carefully before initiating fluid boluses in a hypotensive child.
Profile the hemodynamics — determine whether the child is warm or cold and wet or dry to guide therapy.
Stage cardiogenic shock using the modified SCAI classification; mortality increases from 7% (Stage A) to 36% (Stage E).
Start vasoactives early — initiation in the ED rather than waiting for ICU transfer reduces time to treatment.
Milrinone is the preferred bridging agent for chronic support; epinephrine is the agent of choice for acute resuscitation.
Intubation is high-risk — have ECMO standby available at comprehensive centers.
Prioritize enteral nutrition within 48 hours; withhold parenteral nutrition for 7 days if the enteral route is feasible.
Optimize GDMT before discharge — only approximately 20% of children currently receive triple therapy, representing a major quality gap.
Plan for readmission prevention — 20% of children with HF are readmitted within 30 days, with infants at highest risk.
Screen for behavioral health needs in patients and caregivers throughout the hospitalization.

The 2026 AHA Scientific Statement represents a critical step toward standardizing the care of children with ADHF. As the population of children with congenital and acquired heart disease grows, systematic approaches to evaluation, management, and discharge planning will be essential to improving outcomes in this high-risk population.

Related Calculators

References

Amdani S, Marino BS, Rossano J, et al. Burden of Pediatric Heart Failure in the United States. J Am Coll Cardiol. 2022;79(19):1917-1928.
Puri K, Jentzer JC, Spinner JA, et al. Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children. J Am Coll Cardiol. 2024;83(5):595-608.
Amdani S, Conway J, George K, et al. Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation. 2024;150(2):e33-e50.
Chowdhury RR, Kaur S, Gera R. N-Terminal Pro-B-Type Natriuretic Peptide as a Marker of Severity of Heart Failure in Children With Congenital Heart Diseases. Pediatr Cardiol. 2023;44(8):1716-1720.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421.
Lasa JJ, Dhillon GS, Duff JP, et al. Part 8: Pediatric Advanced Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics. 2026;157(1):e2025074351.
Matsushita FY, Krebs VLJ, de Campos CV, de Vincenzi Gaiolla PV, de Carvalho WB. Reassessing the Role of Milrinone in the Treatment of Heart Failure and Pulmonary Hypertension in Neonates and Children: A Systematic Review and Meta-Analysis. Eur J Pediatr. 2024;183(2):543-555.
Brown S, Nolan O, Poole E, et al. Long-Term Milrinone Therapy in Children With Dilated Cardiomyopathy. Acta Paediatr. 2023;112(6):1298-1303.
Bhaskar P, Davila S, Hoskote A, Thiagarajan R. Use of ECMO for Cardiogenic Shock in Pediatric Population. J Clin Med. 2021;10(8):1573.
Bogle C, Colan SD, Miyamoto SD, et al. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. Circulation. 2023;148(2):174-195.
Ford B, Dore M, Bartlett B. Management of Heart Failure: Updated Guidelines From the AHA/ACC. Am Fam Physician. 2023;108(3):315-320.
U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA Orange Book. Accessed 2026.
Amdani S, Lopez R, Schold JD, Tang WHW. 30- and 60-Day Readmission Rates for Children With Heart Failure in the United States. JACC Heart Fail. 2024;12(1):83-96.
He M, Balbin MT, Kreutzer J, et al. Patient Characteristics Associated With 30-Day Readmission to a Pediatric Cardiac Center. Pediatr Cardiol. 2025 [Epub ahead of print].
Cabrera AG, Price JF, Hong BJ, Jeewa A, et al. Evaluation and Management of the Child With Acute Decompensated Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2026;153:e00-e00.